Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

DAX-044 in Adults With Advanced Solid Tumours: a First-in-human Study of Safety, Dose and Early Anti-cancer Activity.

16. november 2026 oppdatert av: Audax Biosciences Pty. Ltd.

A Phase 1 First-in-human Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumour Activity of Intravenous DAX-044 in Adults With Advanced Solid Tumours.

This is a first-in-human, multicentre, Phase 1, open-label study designed to evaluate the safety and tolerability of DAX-044 as monotherapy, and to determine its maximum tolerated dose, in adults with advanced solid tumours.

Studieoversikt

Status

Har ikke rekruttert ennå

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

This is a first-in-human, multicentre, Phase 1, open-label study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity and anti-tumour activity of DAX-044, a targeted, potency-optimised interleukin-12 (IL-12) immunocytokine, as monotherapy in adults with advanced solid tumours.

Part 1 (dose escalation) will evaluate DAX-044 monotherapy across planned dose levels, using a Bayesian optimal interval (BOIN) design to determine the maximum tolerated dose (MTD). Participants with any of the eligible tumour types are enrolled together into dose-level cohorts. Each participant remains at their allocated dose level; escalation occurs between cohorts only. Additional participants may be enrolled into backfill cohorts at dose levels already cleared for safety.

Part 2 (dose expansion) will further evaluate the safety and anti-tumour activity of DAX-044 monotherapy, at dose levels selected from Part 1, in up to 4 tumour-specific expansion cohorts.

In both parts, DAX-044 is given by intravenous infusion on Day 1 of each 21-day cycle, until disease progression, unacceptable toxicity, withdrawal of consent or sponsor termination, to a maximum of 24 months.

Studietype

Intervensjonell

Registrering (Antatt)

142

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Western Australia
      • Nedlands, Western Australia, Australia, 6009
        • Linear Clinical Research Ltd
        • Ta kontakt med:
        • Hovedetterforsker:
          • Timothy Guy Humphries

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Aged at least 18 years.
  • Histologically or cytologically confirmed locally advanced or metastatic non-small cell lung cancer, gastric or gastro-oesophageal junction adenocarcinoma, squamous cell carcinoma of the head and neck, melanoma other than ocular or uveal, triple-negative breast cancer, castrate-resistant prostate cancer (CRPC), microsatellite stable colorectal cancer, pancreatic ductal adenocarcinoma, or epithelial ovarian cancer. Tumour-type-specific requirements for prior therapy also apply.
  • Measurable disease by RECIST v 1.1, except CRPC, which may be measurable or non-measurable.
  • At least 1 prior line of systemic standard-of-care therapy, with radiographic progression on or after the last line received. CRPC with non-measurable disease must instead show progression of PSA.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Life expectancy greater than 3 months.
  • Able to provide pre-treatment tumour tissue, either archival or as a fresh biopsy.
  • Adequate organ function within 14 days before first dose, including absolute neutrophil count greater than or equal to 1.5 x 10^9/L, platelets greater than or equal to 100 x 10^9/L, haemoglobin greater than or equal to 9 g/dL, bilirubin less than or equal to 1.5 times the upper limit of normal (ULN), transaminases less than or equal to 3 times the ULN (5 times the ULN if liver metastases are present), and creatinine clearance greater than or equal to 50 mL/min.
  • Agreement to use contraception according to the protocol.

Exclusion Criteria:

  • Pregnant, breast-feeding, or planning to become pregnant during the study.
  • Any investigational medicinal product within 30 days, before Cycle 1 Day 1.
  • Part 1 only: more than 4 prior lines of systemic chemotherapy in the advanced or metastatic setting. Part 2 instead applies tumour-type-specific requirements for prior lines of therapy.
  • Uncontrolled brain metastases.
  • Active or past autoimmune disease or immunodeficiency.
  • Idiopathic pulmonary fibrosis, organising pneumonia, drug-induced or idiopathic pneumonia, or evidence of active pneumonia at screening.
  • Severe cardiovascular disease within 6 months.
  • Significant surgical procedures, other than diagnostic surgery, within 4 weeks before the start of study treatment, or expected to require significant surgery during the study period.
  • Known human immunodeficiency virus infection or current active hepatitis B or hepatitis C. Participants with prior HBV infection with negative HBV DNA are eligible. Participants clinically cured of hepatitis C, at least 12 weeks after completing antiviral treatment, are eligible.
  • History of life-threatening toxicity related to prior immune therapy, for example an inhibitor of PD-1 or PD-L1, an anti-CTLA-4 agent, or any other drug targeting T-cell activation or immune checkpoint pathways.
  • A live virus vaccine within the 4 weeks before Cycle 1 Day 1, or plans to receive a live virus vaccine during the study.
  • Corrected QT interval using Fridericia correction greater than 470 milliseconds.
  • Prior treatment with DAX-044 or any interleukin-12-based agent.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Sekvensiell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Part 1 - DAX-044 Monotherapy Dose Escalation

DAX-044 administered at ascending dose levels to participants with advanced solid tumours, to assess safety and tolerability and determine the maximum tolerated dose (MTD). Dose escalation follows a Bayesian optimal interval (BOIN) design.

DAX-044 monotherapy

Eksperimentell: Part 2 - DAX-044 Monotherapy Dose Expansion in Tumour-Specific Cohorts

Part 2 will further evaluate the safety and anti-tumour activity of DAX-044 monotherapy, at dose levels selected from Part 1, in up to 4 tumour-specific expansion cohorts.

DAX-044 monotherapy

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) as Assessed by CTCAE v6.0
Tidsramme: Up to 24 months
Up to 24 months
Maximum Tolerated Dose (MTD) of DAX-044 Based on Dose-Limiting Toxicities (DLTs) (Part 1)
Tidsramme: Up to 24 months
Up to 24 months

Sekundære resultatmål

Resultatmål
Tidsramme
Serum Concentrations of DAX-044
Tidsramme: Up to 24 months
Up to 24 months
Maximum Observed Serum Concentration (Cmax) of DAX-044
Tidsramme: Up to 24 months
Up to 24 months
Time to Maximum Observed Serum Concentration (Tmax) of DAX-044
Tidsramme: Up to 24 months
Up to 24 months
Trough Serum Concentration (Ctrough) of DAX-044
Tidsramme: Up to 24 months
Up to 24 months
Area Under the Serum Concentration Versus Time Curve Over the Dosing Interval (AUCtau) of DAX-044
Tidsramme: Up to 24 months
Up to 24 months
Terminal Half-Life (t1/2) of DAX-044
Tidsramme: Up to 24 months
Up to 24 months
Clearance (CL) of DAX-044
Tidsramme: Up to 24 months
Up to 24 months
Number of Participants With Anti-Drug Antibodies (ADA) to DAX-044
Tidsramme: Up to 24 months
Up to 24 months
Objective Response Rate (ORR) as Assessed by the Investigator per RECIST 1.1
Tidsramme: Up to 24 months
Up to 24 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. februar 2027

Primær fullføring (Antatt)

10. august 2030

Studiet fullført (Antatt)

23. oktober 2030

Datoer for studieregistrering

Først innsendt

16. november 2026

Først innsendt som oppfylte QC-kriteriene

16. november 2026

Først lagt ut (Faktiske)

20. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

20. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

16. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • DAX-044-2601

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .